22.04.2022 14:30:00
|
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic Plan
SAN FRANCISCO, April 22, 2022 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will host an analyst and investor conference call with Nektar executives on Monday, April 25, 2022, at 2:00 p.m. Pacific Standard Time (PST), to outline a new strategic plan for the company and provide updates for the company's research and development pipeline.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through May 27, 2022.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S); (970) 315-0453 (international)
Conference ID: 5888057 (Nektar Therapeutics is the host)
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company developing investigational medicines in oncology, immunology, and inflammatory diseases. The company also has a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at https://www.nektar.com.
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-for-analysts--investors-to-outline-new-strategic-plan-301530770.html
SOURCE Nektar Therapeutics

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
07.03.25 |
NASDAQ Composite Index-Titel Nektar Therapeutics-Aktie: So viel hätte eine Investition in Nektar Therapeutics von vor 3 Jahren gekostet (finanzen.at) | |
04.03.25 |
NASDAQ-Handel NASDAQ Composite beendet den Dienstagshandel im Minus (finanzen.at) | |
04.03.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite am Nachmittag fester (finanzen.at) | |
28.02.25 |
NASDAQ Composite Index-Papier Nektar Therapeutics-Aktie: So viel hätten Anleger an einem Nektar Therapeutics-Investment von vor einem Jahr verdient (finanzen.at) | |
26.02.25 |
Börse New York in Grün: NASDAQ Composite zum Handelsende mit grünem Vorzeichen (finanzen.at) | |
25.02.25 |
Angespannte Stimmung in New York: NASDAQ Composite im Minus (finanzen.at) | |
25.02.25 |
Börse New York: NASDAQ Composite notiert am Mittag im Minus (finanzen.at) | |
24.02.25 |
Verluste in New York: NASDAQ Composite schließt im Minus (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,73 | -2,85% |
|